GrowGeneration (GRWG) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Hello, everyone, and welcome to GrowGeneration's First Quarter twenty twenty five Earnings Conference Call. My name is Joelle, and I will be your conference operator for today's call. At this time, participants are in a listen only mode. Following prepared remarks, we will open the call to questions from analysts with instructions to be given at that time. This conference call is being recorded and a replay of today's call will be ...

DoubleVerify (DV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the DoubleVerify First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Tijo Ingeman, Senior Vice President of Investor Relations. Thank you. You may begin. Speaker1 Good afterno ...

Lisata Therapeutics (LSTA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Welcome to the Losada Therapeutics First Quarter twenty twenty five Financial Results and Business Update Conference Call. Currently, participants are in listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a reminder, this call is being recorded today, Thursday, 05/08/2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 increased by 16% to $16.7 million compared to $14.5 million in Q3 2024, driven by higher demand in material handling and ground support equipment markets [15] - Gross profit for Q3 2025 increased by 32.5% to $5.3 million, with gross margin rising to 32% from 28% in Q3 2024 [15][16] - Net loss for Q3 2025 was $1.9 million, an improvement from a net loss of $3.0 million in Q3 2024 [17] Business Line Data and Key Metrics Changes - Unit growth in material handling and ground support equipment markets was reported at 1025% [15] - Selling and administrative expenses increased to $5.7 million in Q3 2025 from $5.3 million in Q3 2024, primarily due to professional fees related to a multi-year restatement of financial statements [16] Market Data and Key Metrics Changes - The company is experiencing increased interest from Tier 1 customers in adopting lithium-ion solutions for distribution centers, indicating a shift towards electrification despite economic uncertainties [28] Company Strategy and Development Direction - The company has aligned five strategic initiatives: profitable growth, operational efficiencies, solution selling, product innovation, and software/recurring revenue [5][6] - The launch of the G96 solution aims to advance electrification in airline drone support equipment, positioning the company as a technology leader in clean, high-performance ground support equipment [7][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining operational resilience despite tariff pressures and geopolitical complexities, focusing on supplier diversification and domestic assembly capabilities [12][14] - The company anticipates minimal impact from tariff increases in Q4 2025 due to good inventory levels [40] Other Important Information - The company announced a patent award for an AI-based algorithm for Intelligent Battery Lifecycle Maximization, indicating a shift towards becoming a technology-driven energy solutions provider [9][10] Q&A Session Summary Question: Sensitivity of customers to pricing actions from tariffs - Management noted that customers are committed to their ESG goals and transformation efforts, indicating a stable business environment despite tariff impacts [22] Question: Feedback on Sky BMS and potential ROI - Management highlighted that Sky BMS is crucial for customers to realize value, with expected ROI from reduced maintenance visits and better integration with existing technologies [24][25] Question: Adoption of lithium-ion in the forklift market - Management reported increased interest from customers in adopting lithium solutions, with competitors facing challenges due to tariffs, potentially providing a market share advantage [28] Question: Changes from new sales personnel - Management indicated positive changes from new sales personnel, positioning the company as a software provider with strong battery solutions [34] Question: Deployment timeline for G96 model - Management confirmed that the G96 model is in customer testing and production, with expectations for rapid deployment in the GSE market [37]

Corvus Pharmaceuticals (CRVS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, everyone. Thank you for standing by, and welcome to the Carvus Pharmaceuticals first quarter twenty twenty five business update and financial results conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. It is now my pleasure to turn the call over to Zach Kubo of Real Chemistry. Please go ah ...

Financial Data and Key Metrics Changes - Revenue increased to $4.2 million in Q1 2025 from $3.8 million in Q1 2024, primarily due to higher milestone revenue from GenmAb's clinical program [24] - Operating expenses decreased to $23 million from $26.4 million year-over-year, with R&D expenses down to $12.6 million from $14.6 million [25] - Net loss for Q1 2025 was $18.2 million or $0.17 per share, compared to a net loss of $19 million or $0.19 per share in Q1 2024 [26] Business Line Data and Key Metrics Changes - The number of active partners grew to 95, with new deals signed with Harvard's Weiss Institute, Takis Biotech, and Orion Corporation [8] - Total active programs increased to 378, with 33 active clinical programs and approved products as of the end of Q1 [10] Market Data and Key Metrics Changes - The company expects to receive a $3 million upfront payment from Angelini Pharma, with potential milestones exceeding $170 million [9] - The portfolio of post-discovery stage assets has increased by over 39% in the last two years [11] Company Strategy and Development Direction - The launch of the exploration partner access program aims to enhance partner workflows and create new revenue streams [14][21] - The company remains focused on licensing novel discovery technology to the pharmaceutical industry, which is the foundation of its strategy [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong deal flow and the robustness of new partnerships despite broader industry challenges [5] - The company anticipates that the exploration program will be accretive to earnings and cash flow in both the short and long term [23] Other Important Information - The company implemented a reduction in force in early February, resulting in an additional cash outlay of approximately $1 million in Q1 [27] - Guidance for 2025 revenue remains between $20 million and $25 million, excluding contributions from the exploration program [28] Q&A Session Summary Question: What attributed to the strong number of program starts this quarter? - Management noted that continued innovation and the launch of new technologies have driven interest from both new and existing partners [30][31] Question: Is the exploration platform exclusively for existing partners? - Yes, the exploration partner access program is available only to partners within the OmniAb ecosystem [35] Question: Can you provide any benchmarks for potential partners for the exploration program? - Management indicated that while it is difficult to provide exact numbers, they have deep relationships with partners and are targeting those most likely to benefit from the exploration instruments [42] Question: What are the key differentiators of the exploration platform? - Key differentiators include ease of use, high efficiency, and the absence of fluidics, which reduces maintenance issues [48] Question: How do tariffs impact the business? - Management stated that there are minimal impacts from tariffs as the exploration instrument and most parts are manufactured in the U.S. [51] Question: Will new partners also have access to the exploration platform? - Yes, new partners will have access to the exploration platform as they sign up [58]

Financial Data and Key Metrics Changes - Revenue for Q2 increased to $181.7 million, a 62.5% increase year-over-year and a 12% increase quarter-over-quarter [25][26] - Gross profit reached nearly $100 million, up 5% sequentially and more than 24% year-over-year, with a gross margin of 53% [4][26] - The company reported a net loss of $138.8 million, primarily due to a decline in Bitcoin spot prices [27][12] - Adjusted EBITDA was a negative $57.8 million, but operations produced approximately $70 million of positive EBITDA when normalized [27][28] - The marginal cost per Bitcoin rose to approximately $42,600, a 26% increase over the previous quarter [28] Business Line Data and Key Metrics Changes - Bitcoin production for the quarter was 19.57 Bitcoin, a slight decrease of 3.6% year-over-year despite a halving event [25][26] - Average revenue per Bitcoin produced was $92,811, an increase of 69% year-over-year [26] - Cash overhead decreased by 16% quarter-over-quarter [10] Market Data and Key Metrics Changes - Bitcoin traded at approximately $81,000 at quarter-end, down from $93,000 at the start of the year [12] - The company’s Bitcoin treasury now exceeds 12,101 Bitcoin, valued at over $1.2 billion at current prices [31][11] Company Strategy and Development Direction - The company is transitioning from a nearly 100% HODL strategy to using a portion of monthly Bitcoin production to support operations [8][31] - CleanSpark aims to reach 50 exahash by mid-2025 and has plans for further expansion beyond that [10][19] - The company is focused on maintaining a strong balance sheet and avoiding equity dilution, contrasting with peers who rely on such methods [8][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted resilience amid rising energy prices, declining Bitcoin prices, and increasing mining difficulty [12][21] - The company is well-positioned to capitalize on market opportunities, particularly in acquiring smaller miners at attractive valuations due to tariff pressures [15][69] - Management emphasized a disciplined approach to capital management and strategic flexibility in a volatile market environment [19][32] Other Important Information - CleanSpark was ranked number 35 in the Financial Times 2025 list of the 500 fastest-growing companies in the Americas [20] - Institutional ownership in the company increased to nearly 64% following its inclusion in the S&P SmallCap 600 Index [20] Q&A Session Summary Question: Outlook for network cash rate growth in 2025 and CleanSpark's market share - Management noted a plateau effect in network growth but believes CleanSpark is well-positioned to maintain and grow its market share, currently at about 5% [42][43] Question: How the digital asset management team will generate shareholder value - The team is focused on selecting the right partners and utilizing strategies like covered calls to generate cash flow and maintain flexibility [44][45] Question: Impact of competitors pivoting to HPC on mining rig pricing - Management indicated that reduced demand from larger players has created opportunities for CleanSpark to acquire rigs at lower costs, with expectations of continued price decreases [51][54] Question: Coverage of CapEx through Bitcoin sales - Management clarified that monthly operational expenses are around $35 million, and excess revenue from Bitcoin sales can be allocated towards CapEx or debt servicing [55][58] Question: Consideration of using Bitcoin holdings to repurchase shares - Management is open to various capital strategies but prioritizes growing the Bitcoin balance and enhancing shareholder value through operational investments [62][65] Question: Future of Bitcoin-backed facilities and market for acquisitions - Management expressed interest in bolt-on acquisitions, especially if valuations are favorable, and noted that they are always open to opportunities in the market [68][69]

Co-Diagnostics Inc (CODX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Andrew Benson - Head - IRDwight Egan - Chief Executive OfficerBrian Brown - Chief Financial OfficerEduardo Martinez-Montes - Biotechnology Equity Research Associate Operator Thank you for standing by. My name is Cath, and I will be your conference operator today. At this time, I would like to welcome everyone to the CoDiagnostics first quarter twenty twenty five earnings call. All lines have been placed on mute to ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $99.9 million, more than doubled year over year, and was in line with guidance of $94 million to $104 million [9][26] - Non-GAAP gross margin was 30.7%, above the guidance range of 29% to 30.5%, and improved from 28.9% in Q4 2024 and 18.9% in Q1 2024 [29][30] - Non-GAAP net loss for Q1 was $0.9 million or $0.02 per share, compared to a loss of $12 million or $0.31 per share in Q1 2024 [31] Business Line Data and Key Metrics Changes - CATV segment revenue was $64.5 million, up more than six times year over year and increased 24% sequentially, driven by shipments of 1.8 GHz amplifiers [10][26] - Data center products revenue was $32 million, up 11% year over year but down 28% sequentially due to inventory digestion by a major customer [10][26] - Telecom segment revenue was $2.9 million, up 29% year over year but down 17% sequentially [28] Market Data and Key Metrics Changes - 60% of revenue came from CATV products, 32% from data center products, and 3% from FTTH, telecom, and other [26] - Demand for certain 100G products surged in Q1, potentially related to tariff concerns, but supply constraints limited production [20][27] Company Strategy and Development Direction - The company is focused on expanding production capacity for 800G and higher transceivers, with plans to reach approximately 40,000 transceivers per month by mid-2026 [14][15] - The company aims to minimize tariff impacts by assessing supply chain and manufacturing operations, with a commitment to onshore production [17][35] - The company is actively engaging with customers, particularly in the hyperscale data center market, to expand revenue opportunities [19][68] Management's Comments on Operating Environment and Future Outlook - Management noted strong demand in the CATV market and positive long-term growth trends in both CATV and data center markets [12][13] - Tariffs had no material impact on Q1 financials, and management does not expect significant impact in Q2 based on current information [13] - The company expects Q2 revenue to be between $100 million and $110 million, with a modest sequential decrease in CATV revenue and an increase in data center revenue [36] Other Important Information - The company ended Q1 with $66.8 million in cash and equivalents, down from $79.1 million at the end of Q4 2024 [32] - Total debt, excluding convertible debt, was $46.1 million, slightly up from $46 million in the previous quarter [32] - The company raised $98 million net under a new at-the-market offering to fund investments in production and R&D [34] Q&A Session Summary Question: Understanding channel inventory for cable TV products - The company has good knowledge of inventory levels through reports from MSOs and channel partners, and there is an intentional inventory buildup due to tariff situations [38][40] Question: Progress with 800G products - The company expects to ramp up production capacity to about 100,000 pieces per month by the end of the year, with a significant revenue contribution anticipated in the second half [44][45] Question: Manufacturing in China - The company is not manufacturing any products with a country of origin in China for tariff purposes, although some operations occur there [46] Question: Retooling to Motorola style amplifiers - The company is shifting production to Motorola style amplifiers, expecting to have significant inventory of both products by June [54][55] Question: Long-term market for 800G - The market for 800G is expected to grow significantly, with the company positioned to capture a substantial share, particularly with major customers like Amazon [57][76] Question: CapEx needs and funding - The company has completed a significant ATM offering and is exploring other funding options, but remains confident in achieving profitability this year [60][61]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion, with adjusted earnings per diluted share at $33.5, exceeding expectations and reflecting a year-over-year EPS growth of 20% [5][40][42] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth across the business [32][29] - Operating profit for the full year increased 15% to $5.6 billion, with significant contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments [41][42] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment saw revenues increase by 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty product distribution [33][22] - The Prescription Technology Solutions segment reported a revenue increase of 13% to $1.3 billion, with operating profit rising 34% to $285 million, reflecting increased prescription transaction volumes [34][35] - The Medical Surgical Solutions segment experienced a 1% revenue increase to $2.9 billion, with operating profit up 15% to $285 million, benefiting from cost optimization initiatives [37][36] Market Data and Key Metrics Changes - The Canadian business, part of the international segment, reported revenues of $3.5 billion, a decrease of 2% due to the divestiture of certain businesses, but operating profit increased by 9% [38][24] - The company anticipates continued growth in the Canadian distribution business, partially offset by the impact of previous divestitures [58] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of a controlling interest in Prism Vision and Core Ventures, aimed at enhancing community-based care [6][12][49] - A strategic decision was made to separate the Medical Surgical segment into an independent company to enhance operational focus and capital deployment [19][27] - The company plans to continue investing in technology, automation, and AI to improve operational efficiencies and customer service [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to maintain momentum and deliver strong results in fiscal 2026, with anticipated revenue growth of 11% to 15% and operating profit growth of 8% to 12% [43][44] - The company remains committed to maximizing shareholder value through disciplined portfolio management and strategic capital deployment [27][62] Other Important Information - The company returned $3.5 billion to shareholders in fiscal 2025, including $3.1 billion through share repurchases [42] - Free cash flow for the fourth quarter was robust at $7.5 billion, driven by strong operating results [39] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no concrete announcements regarding Medicare Part B impacts, and any potential changes would likely face legal challenges [65][66] Question: Tariff Impacts on Business - Management is closely monitoring the tariff landscape and believes that current assessments have been incorporated into guidance, with no material impact anticipated on fiscal 2026 results [75][81] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [85][88] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in long-term guidance reflects a stable environment for prescription utilization and successful capital deployment in oncology and other specialties [92][96]